Compare Abeona Therapeutics Inc (ABEO) vs Gap Inc (GAP) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Gap Inc — how do they compare? Abeona Therapeutics Inc trades at $6.69 (market cap $373.32M), while Gap Inc trades at $18.37 (market cap $6.86B). The key difference: Gap Inc is far larger — about 18.4× Abeona Therapeutics Inc's market cap, and Gap Inc pays a 3.67% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | GAP | |
|---|---|---|
Market Cap | $373.32M | $6.86B |
Sector | Health | Consumer Cyclical |
52-Week High | $7.23 | $29.13 |
52-Week Low | $4.17 | $18.68 |
Enterprise Value | $228.22M | $9.95B |
Dividend Yield | — | 3.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Gap trades at $19.07, down 0.94% on the day, with a bearish technical signal despite oversold RSI readings. The stock shows strong fundamentals with a P/E of 7.69, net income margin of 6.25%, and robust cash flow. Recent news highlights a turnaround in progress, with nine consecutive positive comps and AI-driven marketing initiatives, though legal investigations and Athleta's rebuild create headwinds.
The outlook is mixed: valuation metrics suggest undervaluation with a consensus price target of $27, but technical weakness and legal risks temper near-term optimism. Earnings growth and digital transformation are key catalysts, while investor sentiment remains cautious amid ongoing legal scrutiny and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Gap Inc
Gap retails apparel, accessories, and personal-care products under the Gap, Old Navy, Banana Republic, and Athleta brands. Old Navy generates more than half of Gap's sales. The firm also operates e-commerce sites, outlet stores, and specialty stores under various Gap names. Gap operates nearly 3,000 stores in North America, Europe, and Asia and franchises about 600 stores in Asia, Europe, Latin America, and other regions. Gap was founded in 1969 and is based in San Francisco.
Read more on GAP →
